Most recently, Chemocentryx initiated a phase Ib trial of their next-generation CCR2 antagonist (CCX872) for non-resectable pancreatic cancer (ClinicalTrials.gov ID: NCT02345408). Here, CCR2 is linked to familial pancreatic carcinoma.